Alzheimer's failure raises questions about disease-modifying strategies

Nat Rev Drug Discov. 2010 Oct;9(10):749-51. doi: 10.1038/nrd3288.
No abstract available

Publication types

  • News

MeSH terms

  • Alanine / analogs & derivatives*
  • Alanine / pharmacology
  • Alanine / therapeutic use
  • Alzheimer Disease / enzymology*
  • Alzheimer Disease / therapy*
  • Amyloid Precursor Protein Secretases / antagonists & inhibitors
  • Azepines / pharmacology
  • Azepines / therapeutic use*
  • Clinical Trials, Phase III as Topic / trends*
  • Drug Industry / trends
  • Humans
  • Skin Neoplasms / chemically induced
  • Treatment Failure

Substances

  • Azepines
  • N2-((2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl)-N1-((7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-L-alaninamide
  • Amyloid Precursor Protein Secretases
  • Alanine